Document text
Principal Investigator: David A Morilak
Organization: SOUTH TEXAS VETERANS HEALTH CARE SYSTEM
Fiscal Year: 2024
Funding agency: Veterans Affairs
Current pharmacological treatments for PTSD and comorbid depression are inadequate. These stress-
related psychiatric illnesses of high significance and impact to the veteran population, and finding more effective
treatments would satisfy a tremendous gap in veterans’ health care. Evidence-based behavioral therapies, such
as exposure therapy, are promising, but they also have limited efficacy. The lack of effective treatment arises,
in part, from our lack of knowledge of the neurobiological mechanisms underlying these illnesses, the altered
regulatory processes that lead to pathology, the neural systems that mediate the dimensions of cognition and
adaptive coping behavior that are disrupted in these illnesses, and the mechanisms responsible for effective
therapeutic response in any modality, pharmacological or behavioral. Such knowledge may inform a more
targeted approach to increase therapeutic efficacy. To better study these processes, in the previous grant period
we developed, validated and characterized extinction learning in rats as a model of exposure therapy in comorbid
PTSD and depression. We demonstrated the efficacy of extinction in reversing behavioral and physiological
deficits following chronic unpredictable stress. We showed that these effects were dependent upon activity in
the medial prefrontal cortex (mPFC) during extinction for the therapeutic effects seen 24 hrs after treatment. And
we showed that the therapeutic effects of extinction were dependent on the induction of de novo protein synthesis
in the mPFC, which we believe represents the initiation of processes related to plasticity and changes in circuit
function in this brain region. In this proposal for renewal, we will characterize the precise circuit-level plasticity
and signaling mechanisms that underlie the therapeutic effects of extinction on a range of behavioral measures
modeling different dimensions of comorbid PTSD and depression after chronic unpredictable stress exposure.
In aim 1, using a virogenetic inhibitory DREADD strategy, we will investigate the role of specific efferent
projections of the infralimbic (IL) and prelimbic (PL) sub-regions of mPFC to target regions that mediate specific
behavioral response domains relevant to comorbid PTSD and depression, and to the therapeutic efficacy of
exposure therapy. In aim 2, we will investigate the role of afferent projections to the IL and PL cortices arising
from the mediodorsal thalamus and the ventral hippocampus in the therapeutic effects of extinction. We will also
test the hypothesis that BDNF signaling during extinction, induced specifically by activity in ventral hippocampal
afferent, initiates signal transduction processes in the mPFC necessary for the plasticity that is ultimately
responsible for the beneficial behavioral effects seen 24 hours after extinction. With this knowledge, in aim 3,
we will then test a rational adjunct treatment strategy combining a sub-effective extinction protocol with a sub-
effective dose of a novel candidate pharmacotherapeutic agent, L-655,708, that activates signaling pathways
and/or neural circuits convergent with those activated by extinction, to determine if this strategy can increase the
efficacy of extinction. We have established the utility of the adjunct therapy strategy to detect enhanced efficacy
using ketamine, an established therapeutic agent. The proposed investigation of potential therapeutic utility of
L-655,708 is a high-risk high-gain undertaking, as the likelihood of success is less clear. L-655,708 is a selective
negative allosteric modulator of the a5 subtype of the GABA-A receptor that is relatively specifically expressed
in the ventral hippocampus, a major afferent to the IL cortex that we believe plays an important role in therapeutic
efficacy after chronic stress. The ultimate goal of this research is to inform the development of more effective
treatments for PTSD and comorbid depression, to improve the quality of life for veterans and their families.
The PI and the MPI are well established VA investigators with a long history of productive collaboration and
complementary expertise in stress neurobiology, psychopharmacology, animal models and systems
neurobiology. They and their labs are ideally suited to the successful conduct of this project.
Terms: <Acoustics><Affective><Afferent Pathways><After Care><After-Treatment><Aftercare><Ammon Horn><Amygdala><Amygdaloid Body><Amygdaloid Nucleus><Amygdaloid structure><Anhedonia><Animal Model><Animal Models and Related Studies><Attention><BDNF><Beds><Behavior Conditioning Therapy><Behavior Modification><Behavior Therapy><Behavior Treatment><Behavioral><Behavioral Conditioning Therapy><Behavioral Modification><Behavioral Therapy><Behavioral Treatment><Brain region><Brain-Derived Neurotrophic Factor><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Chronic><Chronic stress><Cognition><Cognitive><Collaborations><Combined Modality Therapy><Common Rat Strains><Conditioning Therapy><Coping Behavior><Cornu Ammonis><DREADDs><Development><Dimensions><Disease><Disorder><Dose><Down-Regulation><Drug Therapy><Extinction><Family><Future><GABA-A Receptor><GABA-Benzodiazepine Receptors><Goals><Grant><Healthcare><Hippocampus><History><Hour><Impairment><Intracellular Communication and Signaling><Investigation><Investigators><Ketamine><Knowledge><Lateral><Measures><Medial><Mediating><Mental Depression><Mental disorders><Mental health disorders><Microinjections><Modality><Modeling><Multimodal Therapy><Multimodal Treatment><Muscimol Receptors><Neurobiology><Nucleus><Nucleus Accumbens><PTSD><Pathology><Pharmacological Treatment><Pharmacotherapy><Physiologic><Physiological><Play><Post-Traumatic Neuroses><Post-Traumatic Stress Disorders><Posttraumatic Neuroses><Prefrontal Cortex><Process><Productivity><Protein Biosynthesis><Protocol><Protocols documentation><Psychiatric Disease><Psychiatric Disorder><Psychopharmacology><Psychotherapy><QOL><Quality of life><Rat><Rats Mammals><Rattus><Recording of previous events><Research><Research Personnel><Researchers><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><Role><Saccharose><Signal Induction><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Stress><Stress and Coping><Sucrose><System><Testing><Thalamic structure><Thalamus><Therapeutic><Therapeutic Agents><Therapeutic Effect><Treatment Efficacy><Veterans><amygdaloid nuclear complex><associated symptom><behavior intervention><behavior measurement><behavior response><behavioral intervention><behavioral measure><behavioral measurement><behavioral response><biological signal transduction><co-morbid><co-morbid depression><co-morbid symptom><co-morbid with depression><co-morbidity><co-morbidity with depression><co-occuring symptom><combination therapy><combined modality treatment><combined treatment><comorbid depression><comorbid symptom><comorbid with depression><comorbidity><comorbidity with depression><concurrent symptom><cooccuring symptom><coping with stress><depression><depression co-morbidity><depression comorbidity><designer receptors exclusively activated by designer drugs><developmental><drug candidate><drug treatment><effective therapy><effective treatment><efficacy testing><evidence base><flexibility><flexible><health care><high risk><hippocampal><histories><improved><intervention efficacy><learning extinction><mental illness><military veteran><model of animal><multi-modal therapy><multi-modal treatment><negative affect><negative affectivity><neural><neural circuit><neural circuitry><neural mechanism><neurobiological><neurobiological mechanism><neurocircuitry><neuromechanism><neutralizing antibody><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><pharmacologic><post treatment><post-trauma stress disorder><posttrauma stress disorder><preference><protein synthesis><psychiatric illness><psychological disorder><response><response to therapy><response to treatment><social role><stress-related coping><success><symptom association><symptom comorbidity><synaptic circuit><synaptic circuitry><targeted agent><thalamic><therapeutic efficacy><therapeutic evaluation><therapeutic response><therapeutic testing><therapeutically effective><therapy efficacy><therapy response><traumatic neurosis><treatment response><treatment responsiveness><treatment strategy><ventral pathway><ventral processing stream><ventral stream><ventral visual pathway><ventral visual processing stream><ventral visual stream><veteran population>